Tag: cost-effectiveness

The recent decision by the U.K.'s National Institute for Health and Care Excellence (NICE) regarding the cost-effectiveness of the Alzheimer's drug Donanemab, also known as Kisunla, has raised concerns about its accessibility to patients....